Background The appearance and lifelong, chronic nature of psoriasis result in considerable burden to patients, such as sleep impairment, depressive symptoms, negative self-esteem and reduced work productivity. Objectives To examine direct and indirect (mediated) effects of secukinumab vs. ustekinumab on quality of life, work productivity and activity impairment based on psoriasis severity and symptoms. Methods Analyses were based on data from the CLEAR study. Structural equation modelling examined the effects of secukinumab vs. ustekinumab on the Dermatology Life Quality Index (DLQI) and on the Work Productivity and Activity Impairment (WPAI) questionnaire using Psoriasis Area and Severity Index (PASI) severity and symptoms (pain, itching and scaling) as potential mediators. Analyses were conducted primarily for patients achieving a PASI 90 response (90% or greater reduction in PASI from baseline) at week 16 (repeated at week 52) and for PASI 50, 75 and 100. Results Results at weeks 16 and 52 showed that the effect of treatment on change in DLQI score was mediated by the PASI 90 response and by improvements in itching, pain, and scaling. Achieving any PASI response as early as week 16 directly resulted in significantly better WPAI scores. At week 52, both PASI response and improvement in scaling directly resulted in significantly better WPAI scores. Pain, itching and scaling were correlated (r = 0Á51-0Á68); improvement in any of these had a significant effect (directly or indirectly) on WPAI. All results favoured secukinumab over ustekinumab. Conclusions The results underscore the important role of both PASI response and reduction in symptoms on improvements in health-related quality of life and work and daily activity in favour of secukinumab vs. ustekinumab.
Summary
Background The appearance and lifelong, chronic nature of psoriasis result in considerable burden to patients, such as sleep impairment, depressive symptoms, negative self-esteem and reduced work productivity. Objectives To examine direct and indirect (mediated) effects of secukinumab vs. ustekinumab on quality of life, work productivity and activity impairment based on psoriasis severity and symptoms. Methods Analyses were based on data from the CLEAR study. Structural equation modelling examined the effects of secukinumab vs. ustekinumab on the Dermatology Life Quality Index (DLQI) and on the Work Productivity and Activity Impairment (WPAI) questionnaire using Psoriasis Area and Severity Index (PASI) severity and symptoms (pain, itching and scaling) as potential mediators. Analyses were conducted primarily for patients achieving a PASI 90 response (90% or greater reduction in PASI from baseline) at week 16 (repeated at week 52) and for PASI 50, 75 and 100. Results Results at weeks 16 and 52 showed that the effect of treatment on change in DLQI score was mediated by the PASI 90 response and by improvements in itching, pain, and scaling. Achieving any PASI response as early as week 16 directly resulted in significantly better WPAI scores. At week 52, both PASI response and improvement in scaling directly resulted in significantly better WPAI scores. Pain, itching and scaling were correlated (r = 0Á51-0Á68); improvement in any of these had a significant effect (directly or indirectly) on WPAI. All results favoured secukinumab over ustekinumab. Conclusions The results underscore the important role of both PASI response and reduction in symptoms on improvements in health-related quality of life and work and daily activity in favour of secukinumab vs. ustekinumab.
What's already known about this topic?
• There are only weak to moderate correlations between Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores.
• Factors other than area and severity may play a role in patients' evaluations of their health-related quality of life (HRQoL).
• Patients perceive pain, itching and scaling to be the most troubling aspects of their psoriasis.
What does this study add?
• Both PASI response and improved psoriasis-related symptoms of pain, itching and scaling have an important role for improvements in HRQoL and work and daily activity.
• Improvements in PASI, patient-reported symptoms, HRQoL, and work and daily activity were greater for those patients on secukinumab vs. ustekinumab.
The appearance and lifelong, chronic nature of psoriasis result in considerable burden to patients, 1 such as sleep impairment, 2 depressive symptoms, 3, 4 negative self-esteem 1 and reduced work productivity. 5, 6 Assessment of psoriasis severity and response to treatment in clinical trials is typically made using the Psoriasis Area and Severity Index (PASI). 7 However, although PASI provides a composite assessment of the signs and extent of psoriasis, it does not yield information about the effect psoriasis has on patients' lives. 8 The Dermatology
Life Quality Index (DLQI) is the most commonly used instrument to assess the health-related quality of life (HRQoL) of patients with psoriasis. 7, 9 However, increasing evidence confirms only weak to moderate correlations between the PASI and DLQI. 10, 11 This suggests that factors other than objective disease severity may play a role in patients' evaluations of their HRQoL. Previous research has shown that patients perceive pain, itching and scaling to be the most troubling aspects of their psoriasis. 12, 13 These symptoms are correlated with PASI scores 14 but the size of the correlations suggests that they capture unique patient experience not measured by the PASI itself and may affect HRQoL and work and activity impairment.
In a head-to-head clinical trial for the treatment of moderate-to-severe psoriasis, the CLEAR study, secukinumab has demonstrated sustained greater efficacy vs. ustekinumab in clearing skin to week 52; greater improvement in symptoms, HRQoL, work and activity impairment; and a comparable safety profile. 15 The present post hoc analysis from the CLEAR study explored how PASI response and psoriasis symptoms (pain, itching and scaling) affect HRQoL and work and activity impairment using a sophisticated analytic method, structural equation modelling (SEM). Further, the analysis explored how these relationships differ between secukinumab and ustekinumab.
SEM, or analysis of covariance structures, is an analytic technique that allows empirical and simultaneous assessment of hypothesized relationships between observed (or manifest) and unobserved (or latent) variables. The interpretation is based on the overall model, which is comprised of multiple independent and dependent variables. The model-hypothesized relationships (i.e. the model-implied covariances) are compared with the covariance structure of the empirical data to evaluate the goodness-of-fit of the model to the empirical data; the better the fit, the more the model reflects the actual relationships in the data.
Patients and methods

Data
The data for these analyses came from CLEAR, a 52-week, multicentre, randomized, double-blind, head-to-head, parallelgroup superiority trial in moderate-to-severe psoriasis. At baseline, data were available for 336 patients randomized to secukinumab and 339 randomized to ustekinumab. Details of study methods and efficacy/safety results have been previously reported. 15, 16 Data from week 16 were used in the present analyses as this was the primary efficacy time point; data from week 52 were examined to explore the longer-term effects of treatment and psoriasis symptoms.
Measures
Psoriasis Area and Severity Index
The PASI is a clinician-reported measure evaluating the head, trunk, upper limbs and lower limbs for the severity and body surface area coverage of erythema, thickening (plaque elevation, induration) and scaling (desquamation). [17] [18] [19] Improvement was assessed using the percentage of reduction in PASI total score from baseline at each time point, with specific thresholds of 50% (PASI 50), 75% (PASI 75), 90% (PASI 90) and 100% (PASI 100) reductions being the main criteria for improvement. For all PASI thresholds, patients who attained each of the thresholds received a score of one for attaining that threshold, whereas those who failed to attain each threshold were given a score of zero. Thus, a patient who attained PASI 50 at week 16 would receive a one for the PASI 50 variable, but a zero for the PASI 75, 90 and 100 variables. Each model included only one PASI threshold variable at a time, but all patients were included in each model. They would be scored zero or one for each PASI depending on whether they had attained a particular threshold at weeks 16 or 52. Data on PASI were collected at baseline, weeks 1, 2, 3, 4 and every 4 weeks thereafter until week 52. These zero or one scores for PASI response at weeks 16 (primary efficacy time point) and 52 (longer-term effects) were used for this analysis.
Dermatology Life Quality Index
The DLQI is a 10-item patient-reported measure evaluating the extent to which quality of life (QoL) has been affected by skin problems in the previous week. 20 Total and subscale scores (symptoms and feelings, daily activities, leisure, work and school, personal relationships and treatment) are computed. The total DLQI score ranges from zero (no effect on patient's life) to 30 (extremely large effect on patient's life). The DLQI data were collected at baseline and weeks 4, 8, 12, 16, 28 , 48 and 52. The changes in DLQI total score from baseline to weeks 16 and 52 were used for this analysis.
Work Productivity and Activity Impairment-Psoriasis
The Work Productivity and Activity Impairment-Psoriasis (WPAI) is a self-administered questionnaire comprising six questions regarding the effects of psoriasis on the individual's ability to work and perform regular activities, and is based on their experiences in the previous 7 days. 21 Scores were calculated for the per cent of impairment in daily activities or while working ('presenteeism') and work time missed ('absenteeism'). WPAI scores were collected at baseline and weeks 8, 12, 16, 48 and 52. The absolute WPAI scores at weeks 16 and 52 were used in this analysis rather than change from baseline in WPAI scores. The rationale for this was that the WPAI asks about the past 7 days, not including the current day. Thus, it makes more sense to focus on the scores at weeks 16 and 52 when the measure has a 1-week recall at both time points.
Patient's assessment of psoriasis-related pain, itching and scaling
A self-administered, 11-point numeric rating scale (0-10) was used to evaluate the patient's assessment of pain, itching and scaling over the past 24 h. Respondents answered three questions for the assessment of pain, itching and scaling: 'Overall, how severe was your psoriasis-related pain/itching/scaling over the past 24 hours?' A score of zero represented the absence or null end of the pain, itching or scale intensity (i.e. no pain, itching or scaling) and a score of 10 represented the other extreme of pain, itching, or scaling intensity (i.e. pain, itching or scaling as bad as it could be). Patient assessments of pain, itching and scaling were collected at baseline and weeks 1, 2, 3, 4, every 4 weeks to week 28, and again at weeks 48 and 52. Symptom severity scores for psoriasis-related pain, itching and scaling at weeks 16 and 52 were used in this analysis.
Baseline covariates
The following covariates, known to drive HRQoL potentially, were also included in the present analyses: age and sex of the patient; body mass index; duration of psoriasis; presence of psoriatic arthritis at baseline; and previous use of biologics and/or systemics before treatment with secukinumab or ustekinumab in the CLEAR study. These were allowed to covary in each model.
Analyses
The analyses were carried out using SEM, a type of path analysis that involves the use of latent variables (i.e. unobserved variables; also called factors) and manifest variables (i.e. observed variables) to assess the relationships between multiple patientrelevant outcomes simultaneously. 22, 23 We used SEM to assess the direct and indirect (i.e. mediated) differential effects of psoriasis treatment (secukinumab vs. ustekinumab), covariates, PASI response, and changes in patient-reported psoriasis-related symptoms (pain, itching and scaling) on change in DLQI scores from baseline at weeks 16 and 52, and on absolute WPAI scores at weeks 16 and 52. We present PASI 90 results, as PASI 90 was the primary efficacy end point of the CLEAR study, although the SEM analyses were replicated for PASI 50, 75 and 100 responses. All SEM analyses were conducted using Mplus versions 7Á4 and 8 (Muthen & Muthen, Los Angeles, CA, U.S.A.). Descriptive statistics were performed using SAS version 9Á4 (SAS Institute, Cary, NC, U.S.A.).
We hypothesized that the DLQI symptoms and feelings (DLQI-SF) subscale was antecedent to a DLQI Total (revised) 'subscale' combining the remaining five DLQI subscales (daily activities, leisure, work and school, personal relationships and treatment subscales; Fig. 1 ). The logic underlying this set of relationships was that changes in PASI response and psoriasis symptoms would first affect the DLQI-SF subscale (measured by the questions 'Over the last week, how itchy, sore, painful, or stinging has your skin been?' and 'Over the last week, how embarrassed or self-conscious have you been because of your skin?'); the DLQI-SF subscale would then, in turn, affect the remaining subscales of the DLQI. The five remaining subscales were modelled as alternative measures of a revised latent variable for the DLQI Total. We compared the goodness-of-fit statistics for this revised measurement model of the DLQI with those of a model with a single DLQI Total latent variable and the six domains as indicators of this latent variable to assess whether this revised measurement fit the data better.
Three WPAI scores were considered in the SEM model for WPAI: per cent of impairment in daily activities, per cent of impairment while working ('presenteeism') and work time missed ('absenteeism') in the previous 7 days (Fig. 2) .
Models for the DLQI and WPAI as outcomes were analysed separately for two reasons. Firstly, including six domains of the DLQI and three from the WPAI into a single model would make for a very complex set of pathways, visually. The separate models for these outcomes were themselves complex.
Secondly, correlations between the domains of the DLQI and those of the WPAI were, in many cases, as large or larger than the interdomain correlations for each outcome. Consequently, some domains of one outcome would almost be redundant, or at least interchangeable, with those of the other outcome. Clinicians and researchers are familiar with each of these outcome measures on their own, so for conceptual clarity, we analysed these two outcomes in separate models.
Goodness-of-fit tests were used to assess how closely the hypothesized, model-implied relationships fit or represented those in the CLEAR data. In addition to the fit indices, examination of results focused on standardized coefficients (betas ranging from À1 to 0 to +1, where À1 is a perfect inverse relationship between variables, 0 is no relationship, and +1 is a perfect positive relationship; standardized coefficients are interpreted in a similar way as correlation coefficients); this approach enabled direct comparison of the strength of relationships between the variables included in the DLQI and the WPAI models. Additional details are presented in the File S1 (see Supporting Information).
Results
Baseline comparisons
Baseline characteristics and patient-reported outcome scores for patients in the two treatment arms of the CLEAR study were similar (Table 1 ). These data have been presented elsewhere. 16 Change in the Dermatology Life Quality Index score from baseline to weeks 16 and 52 Results for the models of the change in DLQI total score from baseline to week 16 and from baseline to week 52 are presented in Figures 3 and 4 , respectively (for PASI 50, 75 and 100 see Figs S1-6 in the Supporting Information). Note that only paths that are significant at P < 0Á05 are shown in each figure. Goodness-of-fit statistics for the DLQI models were all excellent, indicating that the relationships hypothesized in Figure 1 are representative of those in the CLEAR data. Moreover, the fit statistics were much better for the model where DLQI-SF was antecedent to the DLQI Total (revised) (Tables S1-4; see Supporting Information). This confirms the model hypothesis that if patients feel that their itchy, sore, painful or stinging skin has improved, or if patients feel less embarrassed or less self-conscious about their skin, they will be more likely to carry out usual daily activities and enjoy more normal personal relationships.
Results of the DLQI model at week 16 showed that the impact of psoriasis treatment on DLQI was not direct but was mediated by both PASI response and psoriasis-related symptoms.
Compared with those treated with ustekinumab, patients treated with secukinumab were significantly more likely to achieve a PASI 50, 75, 90, 100 response (b = À0Á08, À0Á14, À0Á22, À0Á17, respectively). Achieving PASI 75 or 90 (but not PASI 50 or PASI 100) significantly improved the DLQI-SF subscale, which in turn significantly improved the DLQI Total (revised) subscale (i.e. the combined total of the other five DLQI subscales). Similarly, improvements in pain, itching and scaling also significantly improved the DLQI-SF subscale (b = 0Á18, 0Á41, 0Á21, respectively; all P < 0Á05), which in turn significantly improved the DLQI Total (revised) subscale (b = 0Á50; P < 0Á05) in favour of secukinumab over ustekinumab. Improvement in itching had the largest effect on the DLQI-SF subscale and on the DLQI Total (revised) via the DLQI-SF subscale, although pain and scaling were also significant. The DLQI Total (revised) subscale was important to patients, with leisure, daily activities and personal relationships subscales being the most important (i.e. they had the highest standardized coefficients). Similar results were seen with the DLQI models at week 52.
Work Productivity and Activity Impairment-Psoriasis scores at week 16 and week 52
Results for the WPAI models at week 16 and at week 52 are presented in Figures 5 and 6 , respectively (for PASI 50, 75 and 100 see Figs S7-12 in the Supporting Information). Note that only paths that are significant at P < 0Á05 are shown in each figure. Goodness-of-fit statistics for the WPAI models were all excellent, indicating that the hypothesized relationships in Figure 2 reflect the data very well.
Results of the WPAI models at week 16 showed more complex relationships between the different variables than was seen with the DLQI models, and that the impact of psoriasis treatment on WPAI was not direct but was mediated by PASI response.
Psoriasis treatment (b = À0Á215) and scaling (b = À0Á257) directly improved PASI 90 response, and patients treated with secukinumab were more likely to achieve a PASI 90 response than those treated with ustekinumab. The effects of improvement in psoriasis symptoms on WPAI scores were completely indirect and were mediated by the improvement in PASI response. When scaling improved, pain and itching improved, and this improvement was more likely for those treated with secukinumab vs. ustekinumab. Compared with ustekinumab, treatment with secukinumab indirectly and significantly improved pain and itching (r % 0Á07 and 0Á09, Fig 3 . Psoriasis Area and Severity Index (PASI) 90, changes in itching, pain and scaling with changes in Dermatology Life Quality Index (DLQI) at week 16. PSA, psoriatic arthritis; BMI, body mass index; DLQI-SF, DLQI -symptoms and feelings subscale; Tx, treatment; rev, revised; sch, school. Variables in squares are observed variables; variable in a circle is a latent variable. Direct effects are depicted as an arrow emanating from an independent variable leading and pointing to a dependent variable (outcome). An indirect effect is depicted as a mediating variable having an arrow pointing to it from an independent variable but also pointing to yet another dependent variable. respectively) via improvements in scaling and, in turn, the observed correlations between improvements in scaling and improvements in pain and itching. Achieving a PASI 90 response directly resulted in less WPAI activity impairment (b = À0Á215) and presenteeism (b = À0Á2). That is, patients who attained a PASI 90 (a score of one vs. zero) had lower WPAI activity impairment and presenteeism scores). Because WPAI activity impairment and presenteeism are significantly correlated with absenteeism in this model, achieving a PASI 90 response also resulted in less absenteeism. Given that scaling has a direct effect on PASI response, improvement in scaling indirectly resulted in lower WPAI activity impairment and less presenteeism.
Results of the models at week 16 were similar for all PASI responses. The results of the WPAI models at week 52 were somewhat different, with both PASI response and symptoms mediating the effects of psoriasis treatment on WPAI scores.
Patients on secukinumab experienced greater improvements in pain, itching and scaling, and were more likely to achieve a PASI 90 response than those on ustekinumab. Improvement in scaling and the achievement of a PASI 90 response directly resulted in lower WPAI activity impairment (b = 0Á115, À0Á223, respectively), and less presenteeism at week 52 (b = 0Á126 and À0Á236, respectively). Improvement in scaling and the achievement of a PASI 90 response indirectly resulted in less absenteeism at week 52 because absenteeism was correlated with WPAI activity impairment (r = 0Á264) and presenteeism (r = 0Á305) in this model. Pain and itching were directly related to psoriasis treatment and were correlated with scaling (which had direct effects on WPAI activity impairment and presenteeism); therefore, pain and itching indirectly resulted in lower WPAI activity impairment, less presenteeism and less absenteeism at week 52. Results of the models at week 52 were similar for all PASI responses.
Discussion
This post hoc analysis of the CLEAR 52-week study indicates that the effects of psoriasis treatment, PASI response and psoriasis-related symptoms on HRQoL and work and activity impairment are complex, often involving indirect but significant relationships. These SEM analyses demonstrated that the superior effect of secukinumab on HRQoL and WPAI over ustekinumab is mediated by its greater efficacy in achieving PASI response and in improving patient-reported psoriasisrelated pain, itching and scaling symptoms. These results complement those recently reported by other investigators that showed greater effect of secukinumab vs. ustekinumab on HRQoL/DLQI and psoriasis symptoms. 24 Griffiths and colleagues 10 reported weak to moderate correlations between DLQI and PASI total scores and noted that changes in QoL do not appear to be captured by PASI or its subscales. We confirm this assumption, highlighting the role of patient-assessed psoriasis symptoms on top of PASI in Only paths significant at P ≤ 0Á05 are shown. Variables in squares are observed variables; variable in a circle is a latent variable. Direct effects are depicted as an arrow emanating from an independent variable leading and pointing to a dependent variable (outcome). An indirect effect is depicted as a mediating variable having an arrow pointing to it from an independent variable but also pointing to yet another dependent variable.
affecting HRQoL and work productivity and activity impairment outcomes. In 2013, Lewis-Beck and colleagues 25 were the first to describe, using SEM, the presence of a direct relationship between psoriasis symptom severity of pain, itching and scaling and HRQoL and work and activity impairment among patients with moderate-to-severe psoriasis. However, the present analyses go well beyond this research by using a full-structural equation model that simultaneously estimates all hypothesized relationships and evaluates the fit of the hypothesized model to the observed data in the CLEAR study without having to use a two-stage analytic approach. Moreover, the current analysis investigates the differential effects of two active treatments for moderate-to-severe psoriasis and the effects at different time points, which, to our knowledge, is rarely explored in SEM analyse. Leonardi and colleagues 26 focused on the effects of pruritus severity only, whereas the present study integrated three bothersome psoriasis-related symptoms and their interactions.
12,13
The confirmation of the hypothesis that the symptoms and feelings subscale was antecedent to a latent variable (factor) representing the remaining five subscales of the DLQI Total (revised) was a notable result of this analysis. Improving skin clearance and psoriasis symptoms first improve the patients' experience with itchy, sore, painful or stinging skin and embarrassment before improving other domains of HRQoL, such as daily activities or personal relationships. Although this seems logical, this measurement model of the DLQI should be explored in future research as it appears to be a novel conception of this measure.
The effects of improvement in psoriasis symptoms on WPAI scores were indirect (mediated) through improvement in PASI response in the models at week 16, but became direct at week 52. This finding may indicate that patients first experience the effects of achieving clear skin on their work and activities followed by the additional effects of improvements in their psoriasis symptoms.
We did not find a relationship between PASI 50 response and changes in the DLQI-SF subscale. This may be caused by the large skew in the distribution of patients, as almost 95% of patients had attained PASI 50 at both week 16 and week 52. Thus, there was little variability for use as a reliable predictor.
Some limitations in the current study are worth noting. As with any SEM, there are implied causal relationships with these models, and interpretation of many of the paths in these Direct effects are depicted as an arrow emanating from an independent variable leading and pointing to a dependent variable (outcome). An indirect effect is depicted as a mediating variable having an arrow pointing to it from an independent variable but also pointing to yet another dependent variable. models is that of causal relationship. Making statements about causality, as always, requires some caution. Second, the CLEAR study was a clinical trial, with specific inclusion/exclusion criteria and controls. It would be valuable to know whether these same relationships hold in real-world situations. In addition, analyses were limited to the variables available in the CLEAR study; other relevant variables might play a role in these relationships, but were not available for these analyses (e.g. localizations of affected plaques in the body).
An additional point to note is that measures with different recall periods were used in these analyses. For example, patient-reported symptoms had a 24-h recall; the DLQI and WPAI had a 7-day recall. However, in the case of the DLQI, we were interested in the changes in patient-reported symptoms from baseline to weeks 16/52 as they related to changes in the DLQI scores for the same periods. Thus, the change scores did not encompass different recall periods, so this is likely to have had little or no effect on the relationships. In the case of the WPAI, we used the absolute score of the three WPAI domains at weeks 16 and 52. Thus, the analyses and interpretations would focus on changes in patient-reported symptoms and their effect on WPAI scores in the week prior to weeks 16 and 52.
Alternative models of these data could be explored using SEM, including growth models whereby such things as trajectories of change in patient-reported symptoms are correlated with trajectories of change in DLQI, or autoregressive models involving week 16 variables (for example patientreported symptoms) regressed on baseline values of the same variables, rather than using change scores. In the former case, the question being addressed is slightly different from what has been examined here. In the latter instance, the models become much more complex than those involving change variables.
We explored whether a psychological variable such as depression could play a role in explaining some of these relationships, following recent findings of an increased likelihood of depressive symptoms or clinical depression among patients with psoriasis. These may be explained in part by the systemic inflammatory responses of psoriasis that increase the risk of brain inflammation. 4, 27, 28 The only psychological variable available from the CLEAR study is the single item from the EuroQol-5D (EQ-5D) that asks about the extent to which the patient feels anxious or depressed today. As an example, the results of the models of the WPAI that included the EQ-5D anxiety/depression variable showed that improvements in pain Direct effects are depicted as an arrow emanating from an independent variable leading and pointing to a dependent variable (outcome). An indirect effect is depicted as a mediating variable having an arrow pointing to it from an independent variable but also pointing to yet another dependent variable.
and scaling directly resulted in less anxiety/depression, which in turn resulted in less activity impairment and impairment while working (presenteeism). However, an argument could be made that improvements in the WPAI also led to improvement of the EQ-5D anxiety/depression domain. It is then not clear if anxiety or depression is a mediating variable with effects on work and activity impairment or if it is itself an outcome of these QoL domains. Further work is needed to understand the role of anxiety and/or depression in patients' outcomes. SEM has multiple advantages, such as the inclusion of multiple dependent variables that can be examined simultaneously with direct and indirect effects of multiple variables being assessed in a single model. The SEM analyses used here represent a powerful and informative analytical method that has helped us obtain a detailed understanding of the differential direct and indirect effects of secukinumab vs. ustekinumab on multiple patient-relevant outcomes simultaneously. These analyses underscore the importance of achieving clear skin and improving psoriasis-related symptoms in benefiting the lives of patients with moderate-to-severe psoriasis.
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